The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move highlighting the accelerating consolidation within the health-tech sector, French software maker Dassault Systemes is reportedly in talks to acquire ArisGlobal. According to Financial Times reports, the potential transaction is valued at approximately $2 billion. The deal involves purchasing the drug-trial software specialist from its current owner, the investment firm Nordic Capital, as Dassault seeks to solidify its strategic footprint in the life sciences and healthcare markets.
This development occurs amid intensifying competition in the healthcare software space, where Dassault faces rivals like Oracle, which completed a $28 billion acquisition of Cerner in 2022 to bolster its medical cloud capabilities. Compared to industry peers, life sciences software providers have seen resilient demand driven by the digital transformation of clinical research, making the $2 billion valuation for ArisGlobal consistent with sector multiples per market data.
Regarding market performance, DASTY shares stood at $21.09 at close on July 15, 2026, having traded within a range of $21 to $21.5 during the session. Investors are now watching for official confirmation of the deal terms, while also monitoring broader catalysts such as the upcoming U.S. Federal Reserve Monetary Policy Report, which could impact financing conditions for large-scale technology acquisitions.